CoChat

Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia

Open access
Das, Shreyasee, Goossens, Julie, Jacobs, Dirk, Dewit, Nele, Pijnenburg, Yolande A. L., In ‘t Veld, Sjors G. J. G., Teunissen, Charlotte E., Vanmechelen, Eugeen · 2023 · Alzheimer's Research & Therapy

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 16 of the 37 sources its claims cite were checked for support.

Abstract

Background: Loss of synaptic functionality has been recently identified as an early-stage indicator of neurological diseases. Consequently, monitoring changes in synaptic protein levels may be relevant for observing disease evolution or treatment responses in patients. Here, we have studied the relationship between fluid biomarkers of neurodegeneration and synaptic dysfunction in patients with Alzheimer’s disease (AD), frontotemporal dementia (FTD), and subjective cognitive decline (SCD). Methods: The exploratory cohort consisted of cerebrospinal fluid (CSF) samples (n = 60) from patients diagnosed with AD (n = 20), FTD (n = 20), and SCD (n = 20) from the Amsterdam Dementia Cohort. We developed two novel immunoassays for the synaptic proteins synaptosomal-associated protein-25 (SNAP25) and vesicle-associated membrane protein-2 (VAMP2). We measured the levels of these biomarkers in CSF, in addition to neuronal pentraxin-2 (NPTX2), glutamate ionotropic receptor-4 (GluR4), and neurogranin (Ng) for this cohort. All in-house immunoassays were validated and analytically qualified prior to clinical application. CSF neurogranin (Ng) was measured using a commercially available ELISA. Results: This pilot study indicated that SNAP25, VAMP2, and Ng may not be specific biomarkers for AD as their levels were significantly elevated in patients with both AD and FTD compared to SCD. Moreover, the strength of the correlations between synaptic proteins was lower in the AD and FTD clinical groups compared to SCD. SNAP25, VAMP2, and Ng correlated strongly with each other as well as with total Tau (Tau) and phosphorylated Tau (PTau) in all three clinical groups. However, this correlation was weakened or absent with NPTX2 and GluR4. None of the synaptic proteins correlated to neurofilament light (NfL) in any clinical group. Conclusion: The correlation of the synaptic biomarkers with CSF Tau and PTau but the lack thereof with NfL implies that distinct pathological pathways may be involved in synaptic versus axonal degeneration. Our results reflect the diversity of synaptic pathology in neurodegenerative dementias.

Overview

CoChat Summary

TL;DR

This pilot study measured CSF synaptic proteins SNAP25, VAMP2, Ng, NPTX2, and GluR4 in patients with AD, FTD, and SCD (n = 60) and found that SNAP25, VAMP2, and Ng were elevated in both AD and FTD versus SCD, with differential correlations to Tau/PTau but not NfL. The authors also developed and analytically validated novel VAMP2 ELISA and SNAP25 Simoa immunoassays.

Key findings

  • CSF SNAP25, VAMP2, and Ng were significantly higher in both AD and FTD than SCD; SNAP25 alone was significantly elevated in AD versus FTD. NPTX2 was significantly lower in FTD than SCD, while GluR4 did not differ across groups.
  • Diagnostic AUCs: SNAP25 was 0.99 for AD vs SCD, 0.83 for FTD vs SCD, and 0.75 for AD vs FTD. Selected panels were SNAP25 alone for AD vs SCD (AUC = 0.99), VAMP2 + NPTX2 for FTD vs SCD (AUC = 0.97), and SNAP25 + VAMP2 for AD vs FTD (AUC = 0.84).
  • SNAP25, VAMP2, and Ng correlated with Tau and PTau in all three clinical groups (Pearson r = 0.94–0.55), but no synaptic protein correlated with NfL in any group. Correlations among synaptic proteins were lower in AD and FTD than in SCD (SCD r = 0.92–0.49; AD/FTD r = 0.73–0.58).
  • In the overall cohort, SNAP25 (Spearman r = −0.57), VAMP2 (r = −0.48), and Ng (r = −0.52) were negatively correlated with MMSE (P < 0.001); in AD patients, NPTX2 correlated with MMSE (r = 0.55, P = 0.012).

Methods

  • Exploratory CSF cohort from the Amsterdam Dementia Cohort: n = 60 patients with AD (n = 20), FTD (n = 20; all “probable behavioral” variant), and SCD (n = 20). Core biomarkers Aβ42, Tau, PTau, and NfL were available; SCD individuals were negative for AD biomarkers.
  • The authors developed a novel VAMP2 sandwich ELISA and a SNAP25 Simoa assay, validated for precision, LLOQ, dilutional linearity, and parallelism, and measured SNAP25, VAMP2, NPTX2, GluR4, and Ng in CSF.
  • Analyses included Kruskal–Wallis with Dunn’s post hoc tests, log transformation, general linear models corrected for age and sex, Pearson/Spearman correlations, ROC/AUC analysis, and Wald’s backward logistic regression for biomarker panels; power was calculated at 88.1%.

Limitations

  • Stated by the authors: small sample size in each clinical group, heterogeneity within the FTD group, and lack of FTD stratification by genetic diversity or disease severity; loss of MMSE associations after stratification may reflect low sample size and overlapping pathologies.
  • Evident from the text: this is a pilot/exploratory, cross-sectional cohort without an independent validation cohort, and the SCD group was younger and had higher MMSE scores than the disease groups.
  • Evident from the text: FTD diagnoses were all probable behavioral variant, and diagnoses were clinical rather than neuropathologically confirmed, which may limit generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13195-023-01212-x

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Schematic representation of the pre- and post-synaptic terminals of neurons. Aβ, amyloid beta; PTau, phosphorylated Tau (at threonine 181); NfL, neurofilament light chain; VAMP2, vesicle-associated membrane protein-2; SNAP25, synaptosomal associated protein-25; SNARE, SNAP Receptor Complex; NPTX2, neuronal pentraxin-2; GluR4, glutamate receptor-4; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor; NMDAR, N-methyl-D-aspartate receptor
Fig. 1 Schematic representation of the pre- and post-synaptic terminals of neurons. Aβ, amyloid beta; PTau, phosphorylated Tau (at threonine 181); NfL, neurofilament light chain; VAMP2, vesicle-associated membrane protein-2; SNAP25, synaptosomal associated protein-25; SNARE, SNAP Receptor Complex; NPTX2, neuronal pentraxin-2; GluR4, glutamate receptor-4; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor; NMDAR, N-methyl-D-aspartate receptorCC BY · PubMed Central
Fig. 2 Scatter plot of the synaptic CSF fluid biomarkers in the three diagnostic groups AD (n = 20), FTD (n = 20), and SCD (n = 20). The biomarker values were log-transformed to fit a normal distribution and the model corrected for age and sex prior to conducting pairwise multiple comparisons. A SNAP25, B VAMP2, C Ng, D NPTX2, and E GluR4. *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 2 Scatter plot of the synaptic CSF fluid biomarkers in the three diagnostic groups AD (n = 20), FTD (n = 20), and SCD (n = 20). The biomarker values were log-transformed to fit a normal distribution and the model corrected for age and sex prior to conducting pairwise multiple comparisons. A SNAP25, B VAMP2, C Ng, D NPTX2, and E GluR4. *P < 0.05, **P < 0.01, ***P < 0.001CC BY · PubMed Central
Fig. 3 ROC curves and AUC values of the synaptic CSF biomarkers among the clinical groups. A AD versus SCD. B FTD versus SCD. C AD versus FTD. ROC, receiver operating characteristics, AUC, area under the curve. *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 3 ROC curves and AUC values of the synaptic CSF biomarkers among the clinical groups. A AD versus SCD. B FTD versus SCD. C AD versus FTD. ROC, receiver operating characteristics, AUC, area under the curve. *P < 0.05, **P < 0.01, ***P < 0.001CC BY · PubMed Central
Fig. 4 Correlation matrix of the CSF biomarkers. Pearson’s correlation was used as all the biomarkers were log-transformed to fit a normal distribution. The significant correlations are indicated in bold. *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 4 Correlation matrix of the CSF biomarkers. Pearson’s correlation was used as all the biomarkers were log-transformed to fit a normal distribution. The significant correlations are indicated in bold. *P < 0.05, **P < 0.01, ***P < 0.001CC BY · PubMed Central
Fig. 5 Correlation matrix of the CSF biomarkers with MMSE scores in the entire cohort and upon stratification into the clinical groups. Spearman’s correlation was used as MMSE scores were not normally distributed even after log transformation. The significant correlations are indicated in bold. *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 5 Correlation matrix of the CSF biomarkers with MMSE scores in the entire cohort and upon stratification into the clinical groups. Spearman’s correlation was used as MMSE scores were not normally distributed even after log transformation. The significant correlations are indicated in bold. *P < 0.05, **P < 0.01, ***P < 0.001CC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 2 Not valid · 15 Not checked · 69 Own results and interpretations

33 more claims

Create a free account to see all 92 claims and to verify the 21 references still open.

See all claims — free account
  • Probably not a substantial claim. 31
  • It may state two separate claims as one. 34

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 34 references

Research works printed but not linked: 1

  1. Jacobs D, Delacourt J, Vanbrabant J, Dewit N, Galasko D, Vanmechelen E. A monoconal antibody based immunoassay for Neuronal Pentraxin2 in CSF. AnnuRevImmunol. 2017;6(2):337–66.

Cited by

See all 52

Metadata

Authors
Das, S., Goossens, J., Jacobs, D., Dewit, N., Pijnenburg, Y. A. L., In ‘t Veld, S. G. J. G., Teunissen, C. E., & Vanmechelen, E.
Affiliations
  • Amsterdam Neuroscience (NL)
  • ADx NeuroSciences (BE)
Corresponding author
Vanmechelen, Eugeen
Venue
Alzheimer's Research & Therapy
Published
2023-03-24
Volume
15
Issue
1
Pages
62-62
ISSN
1758-9193 (ISSN-L)
OpenAlex
W4360863494
Cited by
50
References
34
Citations by year
2026: 3 · 2025: 19 · 2024: 26 · 2023: 2
FWCI
10.13
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
H2020 European Institute of Innovation and Technology (860197, 18HLT09)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
synaptic biomarkers, cerebrospinal fluid, Alzheimer's disease, frontotemporal dementia, subjective cognitive decline, SNAP-25, VAMP2, neurogranin, GluR4, tau protein, phosphorylated tau, neurofilament light chain, neurodegeneration, immunoassay development
MeSH terms
Alzheimer Disease, Humans, Pilot Projects, Biomarkers, Amyloid beta-Peptides, tau Proteins, Vesicle-Associated Membrane Protein 2, Neurogranin, Frontotemporal Dementia, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia. https://app.cochat.ai/papers/10.1186/s13195-023-01212-x
The paper
Das, S., Goossens, J., Jacobs, D., Dewit, N., Pijnenburg, Y. A. L., In ‘t Veld, S. G. J. G., Teunissen, C. E., & Vanmechelen, E. (2023). Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-023-01212-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.